期刊文献+

卷曲霉素治疗耐药结核病作用机制、毒副作用及耐药机制的研究进展 被引量:3

Research Progress on Action Mechanism,Toxic and Side Effects,and Resistance Mechanism of Capreomycin in the Treatment of Drug Resistant Tuberculosis
下载PDF
导出
摘要 耐药结核病的出现给全球范围内结核病防控工作带来前所未有的挑战。耐药结核病需采用二线抗结核药物治疗,而卷曲霉素属注射类药物,是治疗耐药结核病的核心二线抗结核药物之一,但近年来卷曲霉素因耳毒性等毒副作用而在临床应用受限。本文对卷曲霉素治疗耐药结核病的作用机制、毒副作用及耐药机制等进行了综述,以期提高临床对卷曲霉素的认识并合理使用卷曲霉素。 Emergence of drug resistant tuberculosis brings unprecedented challenge in global tuberculosis control.Drug resistant tuberculosis needs to be treated with the second-line anti-tuberculosis drugs,in which injectable capreomycin is one of core drugs,but the clinical application of capreomycin is limited due to its ototoxicity or other toxic and side effects.This paper reviewed the action mechanism,toxic and side effects,and resistance mechanism of capreomycin in the treatment of drug resistant tuberculosis,in order to improve the clinical acquaintance and rational usage of capreomycin.
作者 李秋阳 陈玲 LI Qiuyang;CHEN Ling(Tuberculosis Division,Department of Pulmonary and Critical Care Medicine,the Affiliated Hospital of Zunyi Medical University,Zunyi 563003,China)
出处 《实用心脑肺血管病杂志》 2019年第11期107-110,共4页 Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
基金 国家自然科学基金资助项目(81760003)
关键词 结核 结核分枝杆菌 广泛耐药结核 卷曲霉素 突变 综述 Tuberculosis Mycobacterium tuberculosis Extensively drug-resistant tuberculosis Capreomycin Mutation Review
  • 相关文献

参考文献5

二级参考文献35

  • 1肖和平.耐多药结核病化疗药物的选择与方案的制定[J].中华结核和呼吸杂志,2006,29(8):517-519. 被引量:32
  • 2Marcos AA, Marilia CLV,H6lio RS, et al.Antituberculosis drugs: Drug interactions, adverse effects,and use in special situations. Part 2: Second-line drugs[J].J Bras Pneumol, 2010,36(5):641-656.
  • 3Guidelines for the programmatic raanagement of drug-resistant tuberculosis: Emergency update 2008[M]. WHO/HTM/TB/2008,402.
  • 4Shin S, Furin J, Alc6ntara F, et al. Hypokalemia among patients re-ceiving treatment for muhidrug-resistant tuberculosis[J].Chest, 2004,125(3):974-980.
  • 5Bastian I,Colebunders R. Treatment and prevention of muhidrug-resistant tubereulosis [J].Drugs, 1999,58(4):633.
  • 6Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with muhidrug-resistant tubereulosis[J].Am J Respir Crit Care Med ,2004,169(10): 1103-1109.
  • 7Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative[J].Int J Tuberc Lung Dis, 2004,158(8): 1382-1384.
  • 8国务院办公厅国办发[2011]53号.国务院办公厅关于印发全国结核病防治规划(2011-2015年)的通知.2011-11-17.
  • 9Guidelines for the progammatic management of drug-resistant tuberculosis, 2011 update. Geneva, World Health Organization, 2011 (WHO/ HTM./TB/2011.6).
  • 10匡铁吉,金关甫,宋萍,李伟霞,王仲元.抗利福平结核分枝杆菌的多药耐药性调查[J].微生物学报,1998,38(2):152-154. 被引量:4

共引文献50

同被引文献28

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部